Breaking News Instant updates and real-time market news.

BPMC

Blueprint Medicines

$101.18

3.33 (3.40%)

10:04
04/13/18
04/13
10:04
04/13/18
10:04

Blueprint Medicines treatment of certain lung cancers granted FDA orphan status

Blueprint Medicines' small molecule rearranged during transfection inhibitor was granted orphan designation by the FDA as a treatment of rearranged during transfection-rearranged non-small cell lung cancer, JAK1/2-positive NSCLC, or TRKC-positive NSCLC, according to a post to the agency's website. Reference Link

BPMC Blueprint Medicines
$101.18

3.33 (3.40%)

11/01/17
ADAM
11/01/17
NO CHANGE
Target $80
ADAM
Buy
Blueprint Medicines price target raised to $80 from $66 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Blueprint Medicines to $80 from $66 ahead of two meaningful clinical trial updates that are due out by year-end. She continues to view the company's pipeline of novel, rationally designed, targeted kinase inhibitors as attractive and reiterated her Buy rating on Blueprint Medicines shares.
11/06/17
WEDB
11/06/17
NO CHANGE
Target $82
WEDB
Outperform
Blueprint Medicines price target raised to $82 from $70 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Blueprint Medicines to $82 from $70 after data in ASH abstract shows BLU-285 benefit in multiple mastocytosis burden measures that appear comparatively better than that achievable with midostaurin. The analyst expects ASH presentation to confirm high response rates that support an accelerated registration path. He reiterates an Outperform rating on the shares.
12/11/17
JMPS
12/11/17
NO CHANGE
Target $97
JMPS
Outperform
Blueprint Medicines price target raised to $97 from $88 at JMP Securities
After Blueprint Medicines presented updated Phase I data for avapritinib in patients with advanced systemic mastocytosis during the American Society of Hematology meeting, JMP Securities analyst Michael King raised his price target on the stock to $97 from $88, stating that robust clinical efficacy was demonstrated while the safety and tolerability profile was consistent with prior experience. The analyst, who sees an increased probability of success for avapritinib in the advanced systemic mastocytosis indication, keeps an Outperform rating on Blueprint shares.
12/11/17
GSCO
12/11/17
NO CHANGE
Target $99
GSCO
Buy
Blueprint Medicines price target rasied to $99 from $82 at Goldman Sachs
Goldman analyst Terence Flynn raised Buy rated Blueprint Medicines' price target to $99 from $82 to reflect the probability of success for BLU-285 and BLU-667 and M&A potential.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$52.12

0.7 (1.36%)

08:25
10/15/18
10/15
08:25
10/15/18
08:25
Upgrade
Wells Fargo rating change  »

Wells Fargo upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 21

    Oct

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

CVS

CVS Health

$74.49

1.33 (1.82%)

08:25
10/15/18
10/15
08:25
10/15/18
08:25
Conference/Events
Economic Club of Washington, D.C. to hold luncheon meeting »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

WTI

W&T Offshore

$7.38

0.12 (1.65%)

08:24
10/15/18
10/15
08:24
10/15/18
08:24
Upgrade
W&T Offshore rating change  »

W&T Offshore upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYME

Tyme Technologies

$2.52

-0.11 (-4.18%)

08:24
10/15/18
10/15
08:24
10/15/18
08:24
Hot Stocks
Tyme Technologies appoints Michele Korfin as CCO »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDC

Teradata

$35.00

0.87 (2.55%)

08:24
10/15/18
10/15
08:24
10/15/18
08:24
Conference/Events
Teradata to hold customer conference »

Teradata Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 01

    Nov

AMTD

TD Ameritrade

$50.52

0.72 (1.45%)

08:23
10/15/18
10/15
08:23
10/15/18
08:23
Conference/Events
TD Ameritrade to hold a daily program »

TD Ameritrade Network, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IMPV

Imperva

$55.32

0.05 (0.09%)

08:21
10/15/18
10/15
08:21
10/15/18
08:21
Downgrade
Imperva rating change  »

Imperva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 13

    Nov

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:21
10/15/18
10/15
08:21
10/15/18
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFS

Discover

$74.60

0.365 (0.49%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Hot Stocks
Discover reports September charge-off rate 3.2% vs. 3.1% last month »

Reports September 30 or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$188.69

1.55 (0.83%)

08:20
10/15/18
10/15
08:20
10/15/18
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
10/15/18
10/15
08:20
10/15/18
08:20
General news
NY Empire State index preview: »

NY Empire State index…

XLK

Technology Select Sector SPDR

$70.83

2.15 (3.13%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDAY

Ceridian

$36.23

0.53 (1.48%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Conference/Events
Ceridian to hold a conference »

INSIGHTS 2018 will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

XLE

Energy Select Sector SPDR

$72.95

0.2 (0.27%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$108.56

2.05 (1.92%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$53.78

0.18 (0.34%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$93.18

1.37 (1.49%)

08:19
10/15/18
10/15
08:19
10/15/18
08:19
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAS

Hasbro

$98.33

0.45 (0.46%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Recommendations
Hasbro analyst commentary  »

Hasbro new digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

XLU

Utilities SPDR

$52.97

-0.04 (-0.08%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$52.38

0.29 (0.56%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$91.07

1.37 (1.53%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GAIN

Gladstone Investment

$10.57

-0.13 (-1.22%)

08:18
10/15/18
10/15
08:18
10/15/18
08:18
Hot Stocks
Gladstone Investment makes additional investment in portfolio company »

Gladstone Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.